We are currently collaborating with the neuropediatrics group (Dr. F. Munell) in the development of innovative gene therapy approaches for congenital muscular dystrophy type 1A (MDC1A). Also, in collaboration with Dr. J. Verdaguer (Universitat de Lleida) we are investigating the mechanism of action and potential applications of a recently discovered family of small peptides derived from intermediate filaments that show potent cytotoxic. immunostimulatory, and transduction enhancing activities.
Group Leader
Jordi Barquinero Mañez
PhD Students
Rocio Piñera Moreno Penelope Romero Duque
1
PUBLICATIONS
6
IMPACT FACTOR
5.70
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Parés M, Fornaguera C, Vila-Julià F, Oh S, H Y Fan S, K Tam Y, Comes N, Vidal F, Martí R, Borrós S, Barquinero J
Preclinical Assessment of a Gene-Editing Approach in a Mouse Model of Mitochondrial Neurogastrointestinal Encephalomyopathy
Hum Gene Ther, 2021, 32: 1210-23
DOI: DOI: 10.1089/hum.2021.152
IF: 5.695
Development of a novel gene therapy strategy and clinical trial readiness of a cohort of patients with merosin-deficient congenital muscular dystrophy
Principal Investigator: Jordi Barquinero, Francina Munell
Agency: ISCIII
Funding: 139,150€
Period: 2020-2022
Development of vectors and preclinical strategies of gene therapy for congenital muscular dystrophy 1A
Principal Investigator: Jordi Barquinero
Agency: Ajuntament de Castellbisbal / Impulsa'T
Funding: 20,000€
Period: 2021
Intermediate Filament-Derived Peptides and Their Uses
Priority Number: PCT/EP2020/068052 (WO 2020/260603A1)
Priority Date: 26/12/2021
Applicants: Universitat De Lleida, Institut De Recerca Biomèdica De Lleida Fundació Dr Pifarré, Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol, Fundació Hospital Universitari Vall D'hebron - Institut De Recerca
